PTC Therapeutics, Inc.
- Jurisdiction
United States - LEI
549300UJLWOIWFDGB318 - ISIN
US69366J2006 (PTCT )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
9
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Read full profile
Fundamentals
- Net revenue
€1.51B - Gross margin
96.7% - EBIT
€612.73M - EBIT margin
40.7% - Net income
€536.65M - Net margin
35.6%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Jacobson Allan Steven | N/A |
|
|
|
|
| Boulding Mark Elliott | EXEC. VP AND CLO |
|
|
|
|
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
|
|
|
|
| Gravier Pierre | CHIEF FINANCIAL OFFICER |
|
|
|
|
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |